CoChat
Sign Up
Cited by 59

Trophic factors therapy in Parkinson's disease

Ramaswamy, Shilpa, Soderstrom, Katherine E., Kordower, Jeffrey H.·2009·Progress in Brain Research
DOI 10.1016/s0079-6123(09)17514-3PMC PMC3430519
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0079-6123(09)17514-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GDNF can protect dopaminergic neurons against oxidative and metabolic stress in experimental models of Parkinson's disease.

    “GDNF can protect dopaminergic neurons against oxidative and metabolic stress in experimental models of Parkinson’s disease (Ramaswamy et al., 2009).”

    From Evidence for miR‐181 involvement in neuroinflammatory responses of astrocytes (2013) · cites this paper as Ramaswamy et al., 2009

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. Ai Y Markesbery W Zhang Z Grondin R Elseberry D Gerhardt GA 2003 Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects The Journal of Comparative Neurology 461 250 261 12724841
  2. Akerud P Alberch J Eketjall S Wagner J Arenas E 1999 Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons Journal of Neurochemistry 73 70 78 10386956
  3. Bilang-Bleuel A Revah F Colin P Locquet I Robert JJ Mallet J 1997 Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease Proceedings of the National Academy of Sciences of the United States of America 94 8818 8823 9238061 PMC23145
  4. Burazin TC Gundlach AL 1999 Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum Brain Research Molecular Brain Research 73 151 171 10581409
  5. Choi-Lundberg DL Lin Q Chang YN Chiang YL Hay CM Mohajeri H 1997 Dopaminergic neurons protected from degeneration by GDNF gene therapy Science 275 838 841 9012352
  6. Choi-Lundberg DL Lin Q Schallert T Crippens D Davidson BL Chang YN 1998 Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor Experimental Neurology 154 261 275 9878166
  7. Dowd E Monville C Torres EM Wong LF Azzouz M Mazarakis ND 2005 Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model The European Journal of Neuroscience 22 2587 2595 16307601
  8. Eslamboli A Cummings RM Ridley RM Baker HF Muzyczka N Burger C 2003 Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus) Experimental Neurology 184 536 548 14637123
  9. Gash DM Zhang Z Ai Y Grondin R Coffey R Gerhardt GA 2005 Trophic factor distribution predicts functional recovery in parkinsonian monkeys Annals of Neurology 58 224 233 16049934
  10. Gasmi M Brandon EP Herzog CD Wilson A Bishop KM Hofer EK 2007a AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson’s disease Neurobiology of Disease 27 67 76 17532642
  11. Gasmi M Herzog CD Brandon EP Cunningham JJ Ramirez GA Ketchum ET 2007b Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease Molecular Therapy 15 62 68 17164776
  12. Georgievska B Kirik D Bjorklund A 2002a Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer Experimental Neurology 177 461 474 12429192
  13. Georgievska B Kirik D Rosenblad C Lundberg C Bjorklund A 2002b Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector Neuroreport 13 75 82 11924898
  14. Grondin R Zhang Z Yi A Cass WA Maswood N Andersen AH 2002 Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys Brain 125 2191 2201 12244077
  15. Hamilton JF Morrison PF Chen MY Harvey-White J Pernaute RS Phillips H 2001 Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin Experimental Neurology 168 155 161 11170730
  16. Herzog CD Dass B Holden JE Stansell J III Gasmi M Tuszynski MH 2007 Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys Movement Disorders 22 1124 1132 17443702
  17. Horger BA Nishimura MC Armanini MP Wang LC Poulsen KT Rosenblad C 1998 Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons The Journal of Neuroscience 18 4929 4937 9634558 PMC6792569
  18. Hwang DY Ardayfio P Kang UJ Semina EV Kim KS 2003 Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice Brain Research Molecular Brain Research 114 123 131 12829322
  19. Kearns CM Gash DM 1995 GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo Brain Research 672 104 111 7749731
  20. Kirik D Rosenblad C Bjorklund A 2000a Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor The European Journal of Neuroscience 12 3871 3882 11069582
  21. Kirik D Rosenblad C Bjorklund A Mandel RJ 2000b Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system The Journal of Neuroscience 20 4686 4700 10844038 PMC6772474
  22. Kordower JH Emborg ME Bloch J Ma SY Chu Y Leventhal L 2000 Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease Science 290 767 773 11052933
  23. Kordower JH Herzog CD Dass B Bakay RA Stansell J III Gasmi M 2006 Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys Annals of Neurology 60 706 715 17192932
  24. Kordower JH Palfi S Chen EY Ma SY Sendera T Cochran EJ 1999 Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease Annals of Neurology 46 419 424 10482276
  25. Lang AE Gill S Patel NK Lozano A Nutt JG Penn R 2006 Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Annals of Neurology 59 459 466 16429411
  26. Lin LF Doherty DH Lile JD Bektesh S Collins F 1993 GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1130 1132 8493557
  27. Liu WG Lu GQ Li B Chen SD 2007 Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson’s disease Parkinsonism & Related Disorders 13 77 88 16963309
  28. Lo BC Deglon N Pralong W Aebischer P 2004 Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson’s disease Neurobiology of Disease 17 283 289 15474365
  29. Lo BC Ridet JL Schneider BL Deglon N Aebischer P 2002 α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease Proceedings of the National Academy of Sciences of the United States of America 99 10813 10818 12122208 PMC125054
  30. Love S Plaha P Patel NK Hotton GR Brooks DJ Gill SS 2005 Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain Nature Medicine 11 703 704 16015352
  31. Mandel RJ Spratt SK Snyder RO Leff SE 1997 Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats Proceedings of the National Academy of Sciences of the United States of America 94 14083 14088 9391156 PMC28436
  32. Marks WJ Jr Ostrem JL Verhagen L Starr PA Larson PS Bakay RA 2008 Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial Lancet Neurology 7 400 408 18387850
  33. Maswood N Grondin R Zhang Z Stanford JA Surgener SP Gash DM 2002 Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys Neurobiology of Aging 23 881 889 12392792
  34. Nutt JG Burchiel KJ Comella CL Jankovic J Lang AE Laws ER Jr 2003 Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 69 73 12525720
  35. Oiwa Y Yoshimura R Nakai K Itakura T 2002 Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease Brain Research 947 271 283 12176170
  36. Pascual A Hidalgo-Figueroa M Piruat JI Pintado CO Gomez-Diaz R Lopez-Barneo J 2008 Absolute requirement of GDNF for adult catecholaminergic neuron survival Nature Neuroscience 11 755 761 18536709
  37. Patel NK Bunnage M Plaha P Svendsen CN Heywood P Gill SS 2005 Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study Annals of Neurology 57 298 302 15668979
  38. Rosenblad C Kirik D Devaux B Moffat B Phillips HS Bjorklund A 1999 Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle The European Journal of Neuroscience 11 1554 1566 10215908
  39. Salvatore MF Ai Y Fischer B Zhang AM Grondin RC Zhang Z 2006 Point source concentration of GDNF may explain failure of phase II clinical trial Experimental Neurology 202 497 505 16962582
  40. Sariola H Saarma M 2003 Novel functions and signalling pathways for GDNF Journal of Cell Science 116 3855 3862 12953054
  41. Sauer H Rosenblad C Bjorklund A 1995 Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion Proceedings of the National Academy of Sciences of the United States of America 92 8935 8939 7568047 PMC41082
  42. Slevin JT Gash DM Smith CD Gerhardt GA Kryscio R Chebrolu H 2007 Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal Journal of Neurosurgery 106 614 620 17432712
  43. Tseng JL Bruhn SL Zurn AD Aebischer P 1998 Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy Neuroreport 9 1817 1822 9665607
  44. Wang L Muramatsu S Lu Y Ikeguchi K Fujimoto K Okada T 2002 Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s disease Gene Therapy 9 381 389 11960314
  45. Ye M Wang XJ Zhang YH Lu GQ Liang L Xu JY 2007 Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson’s disease Brain Research 1142 206 216 17336273

Cited by

Sorted by citations

Authors
Ramaswamy, S., Soderstrom, K. E., & Kordower, J. H.
Venue
Progress in Brain Research
Publisher
Elsevier
Published
2009
Pages
201-216
ISSN
0079-6123
DOI
10.1016/s0079-6123(09)17514-3
PMC
PMC3430519
Cited by
59
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review